| Quantity | 1 mg, 5 mg, 10 mg, 25 mg, 50 mg | 500 µ, g, 1 mg, 5 mg, 10 mg | 500 µ, g, 1 mg, 5 mg | 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | 5 mg, 10 mg, 25 mg |
| Description | T7 peptide (Tumstatin (74-98), human) TFA is an endothelial cell-specific inhibitor. T7 peptide TFA interacts with αVβ3 integrin to inhibit the FAK, PI3-kinase, PKB/Akt, and mTOR signaling pathways in endothelial cells, ultimately suppressing protein synthesis and inducing apoptosis[1] | β-Amyloid (1-40) TFA is a primary protein in plaques found in the brains of patients with Alzheimer's disease[1] | HRP-Streptavidin is a conjugate of HRP and Streptavidin. HRP-Streptavidin can be used for detection of biotinylated proteins and generates light signal[1] | Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis[1][2][3][4][5][6]... Read More | Protease-Activated Receptor-4 is the agonist of proteinase-activated receptor-4 (PAR4) |